Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $18.67 Average PT from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $18.6667.

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $5.01 on Friday. The company’s 50 day moving average price is $4.97 and its 200 day moving average price is $4.15. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $7.75. The company has a market capitalization of $123.83 million, a PE ratio of -1.46 and a beta of 2.16.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.03. On average, equities analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC lifted its holdings in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the fourth quarter worth approximately $341,000. Jane Street Group LLC bought a new position in Artiva Biotherapeutics during the second quarter valued at approximately $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in Artiva Biotherapeutics during the third quarter valued at approximately $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.